GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ginkgo Bioworks Holdings Inc (NYSE:DNA) » Definitions » Return-on-Tangible-Equity

Ginkgo Bioworks Holdings (Ginkgo Bioworks Holdings) Return-on-Tangible-Equity : -82.23% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Ginkgo Bioworks Holdings Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Ginkgo Bioworks Holdings's annualized net income for the quarter that ended in Dec. 2023 was $-846.8 Mil. Ginkgo Bioworks Holdings's average shareholder tangible equity for the quarter that ended in Dec. 2023 was $1,029.8 Mil. Therefore, Ginkgo Bioworks Holdings's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 was -82.23%.

The historical rank and industry rank for Ginkgo Bioworks Holdings's Return-on-Tangible-Equity or its related term are showing as below:

DNA' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -190.77   Med: -104.82   Max: -27.75
Current: -69.71

During the past 5 years, Ginkgo Bioworks Holdings's highest Return-on-Tangible-Equity was -27.75%. The lowest was -190.77%. And the median was -104.82%.

DNA's Return-on-Tangible-Equity is ranked worse than
61.96% of 1309 companies
in the Biotechnology industry
Industry Median: -48.28 vs DNA: -69.71

Ginkgo Bioworks Holdings Return-on-Tangible-Equity Historical Data

The historical data trend for Ginkgo Bioworks Holdings's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ginkgo Bioworks Holdings Return-on-Tangible-Equity Chart

Ginkgo Bioworks Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
- -27.75 -190.77 -139.06 -70.58

Ginkgo Bioworks Holdings Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -48.02 -54.56 -49.88 -99.55 -82.23

Competitive Comparison of Ginkgo Bioworks Holdings's Return-on-Tangible-Equity

For the Biotechnology subindustry, Ginkgo Bioworks Holdings's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ginkgo Bioworks Holdings's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ginkgo Bioworks Holdings's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Ginkgo Bioworks Holdings's Return-on-Tangible-Equity falls into.



Ginkgo Bioworks Holdings Return-on-Tangible-Equity Calculation

Ginkgo Bioworks Holdings's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-892.869/( (1565.026+965.173 )/ 2 )
=-892.869/1265.0995
=-70.58 %

Ginkgo Bioworks Holdings's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=-846.776/( (1094.458+965.173)/ 2 )
=-846.776/1029.8155
=-82.23 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Ginkgo Bioworks Holdings  (NYSE:DNA) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Ginkgo Bioworks Holdings Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Ginkgo Bioworks Holdings's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Ginkgo Bioworks Holdings (Ginkgo Bioworks Holdings) Business Description

Traded in Other Exchanges
Address
27 Drydock Avenue, 8th Floor, Boston, MA, USA, 02210
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Foundry and Biosecurity. The Biosecurity segment generates the majority of revenue.
Executives
Jason R Kelly director, officer: CEO & Founder 667 MADISON AVENUE, C/O CORVEX MANAGEMENT LP, NEW YORK NY 10065
Mark E. Dmytruk officer: Chief Financial Officer C/O SOARING EAGLE ACQUISITION CORP., 955 FIFTH AVENUE, NEW YORK NY 10075
Barry Canton 10 percent owner C/O GINKGO BIOWORKS, INC., 27 DRYDOCK AVENUE, 8TH FLOOR, BOSTON MA 02210
Reshma P. Shetty director, 10 percent owner, officer: President, COO & Founder C/O SOARING EAGLE ACQUISITION CORP., 955 FIFTH AVENUE, NEW YORK NY 10075
Christian O Henry director 9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Harry Sloan director, officer: CEO, Chairman 1450 2ND STREET, SUITE 247, SANTA MONICA CA 90401
Shyam Sankar director C/O PALANTIR TECHNOLOGIES INC., 1200 17TH STREET, FLOOR 15, DENVER CO 80202
Steven P. Coen officer: Chief Accounting Officer C/O GINKGO BIOWORKS HOLDINGS, INC., 27 DRYDOCK AVENUE, 8TH FLOOR, BOSTON MA 02210
Marie E. Fallon officer: Chief Accounting Officer C/O GINKGO BIOWORKS, INC., 27 DRYDOCK AVENUE, 8TH FLOOR, BOSTON MA 02210
Marijn E Dekkers director GENERAL ELECTRIC COMPANY, 41 FARNSWORTH STREET, BOSTON MA 02210
Kathy Hopinkah Hannan director ANNALY CAPITAL MANAGEMENT, INC., 1211 AVE. OF THE AMERICAS, NEW YORK NY 10036
David C. Ott 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Parent Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Gp Llc 10 percent owner 55 RAILROAD AVENUE, GREENWICH CT 06830